Showing results (1-10 of 9) with videos related to
Sort By:
Pageof 1
CNS Spectrums|January 22, 2008
Open-label, concomitant use of lamotrigine and other medications for bipolar disorderCharles L Bowden, Suzanne Edwards, Gary EvoniukBMJ (Clinical Research Ed.)|April 23, 2017
Impact of study outcome on submission and acceptance metrics for peer reviewed medical journals: six year retrospective review of all completed GlaxoSmithKline human drug research studiesGary Evoniuk, Bernadette Mansi, Barbara DeCastro, et al.CNS Spectrums|May 25, 2013
A factor analytic study in bipolar depression, and response to lamotriginePhilip B Mitchell, Dusan Hadzi-Pavlovic, Gary Evoniuk, et al.Journal of Affective Disorders|November 16, 2007
Discovery and development of lamotrigine for bipolar disorder: a story of serendipity, clinical observations, risk taking, and persistenceRichard H Weisler, Joseph R Calabrese, Charles L Bowden, et al.The American Journal of Geriatric Psychiatry : Official Journal of the American Association for Geriatric Psychiatry|April 23, 2005
Maintenance treatment outcomes in older patients with bipolar I disorderMartha Sajatovic, Laszlo Gyulai, Joseph R Calabrese, et al.Journal of Psychopharmacology (Oxford, England)|November 27, 2009
Double-blind, placebo-controlled comparison of the antidepressant efficacy and tolerability of bupropion XR and venlafaxine XRKaren Hewett, Michelle D Gee, Alok Krishen, et al.Journal of Psychopharmacology (Oxford, England)|November 4, 2011
Efficacy, safety, and tolerability of a triple reuptake inhibitor GSK372475 in the treatment of patients with major depressive disorder: two randomized, placebo- and active-controlled clinical trialsSusan Learned, Ole Graff, Suraja Roychowdhury, et al.Journal of Psychopharmacology (Oxford, England)|March 30, 2013
Full central neurokinin-1 receptor blockade is required for efficacy in depression: evidence from orvepitant clinical studiesEmiliangelo Ratti, Paolo Bettica, Robert Alexander, et al.Journal of Affective Disorders|November 13, 2010
Clinical value of early partial symptomatic improvement in the prediction of response and remission during short-term treatment trials in 3369 subjects with bipolar I or II depressionDavid E Kemp, Stephen J Ganocy, Martin Brecher, et al.Pageof 1